ClinicalTrials.gg
CompletedNCT06379347HOCUS-POCUSUpdated Oct 30, 2026

HOspitalized Patients and Clinical flUid Status, Assessment Using Point Of Care UltraSound

An observational study in Volume Status, sponsored by Flevoziekenhuis. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Flevoziekenhuis · Observational

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
98
Ages
18 Years and older
Sex
All
01

Study summary

Point of care ultrasound (POCUS) of the inferior vena cava (IVC) is a tool for assessing volume status through ultrasonography. Using a point of care ultrasound device, the physician can perform an ultrasound of the vena cava at the bedside. Previous research has demonstrated a correlation between right atrial pressure and the vena cava's diameter. Nonetheless, the majority of research has been conducted in critically ill populations to predict fluid responsiveness in patients with more complex hemodynamics. There is limited data available on the value of IVC ultrasound in the sub-acute setting on the regular ward for clinical decision-making regarding whether a patient is hypovolemic or hypervolemic. This study's objective is to assess the diagnostic utility of point-of-care ultrasonography of the IVC, by using a standardized methodology, performed by qualified ward physicians in a conventional nursing ward.

Read the detailed description

The study will be carried out on patients over the age of 18 who were admitted to the general ward between for at least 24 hours and who had a clinical indication for an IVC ultrasound. Patients are informed through an informed consent form and are given the opportunity to opt-out. When there are no objections, the patient's data is collected for the study. Patients who are using vasopressors at the time of the ultrasound are excluded from the study. In addition, patients who require invasive or non-invasive ventilation (optiflow, CPAP, BPAP) are also excluded.

The ultrasounds are performed by trained physicians based on a standard operating procedure. The longitudinal portion of the IVC is scanned and a cine loop of 10 seconds is made during a respiratory cycle to determine the diameter of the IVC (dIVC). After the recording is paused, the dIVC will be measured 2 cm caudal to the junction of the hepatic vein and IVC to standardize the measurements. Measurements are taken at peak expiration (dIVCe) and inspiration (dIVCi) by measuring the vein lumen at one respiratory cycle from one interior wall to the opposite interior wall.

Data is collected at the time of admission and after 48 hours (or prematurely if the patient is discharged). During the initial assessment, the patient's demographics, clinical data, physical examination, vitals , laboratory parameters, and the POCUS IVC (minimal and maximal diameter, percentage collapse) are registered. The Charlson Comorbidity Index is used to quantify the severity of comorbidities in the patients. Additionally, the patient's overall health status is measured by the ECOG Performance Status Scale.

Once the initial measurements are done, a clinical diagnosis of the patient's volume status will be established. 48 hours later, more data will be gathered for the follow-up. The data includes vitals and laboratory parameters. It is also noted whether the POCUS influenced the management of treatment (IV fluid or diuretic therapy) of each patient. Following this assessment, a clinical diagnosis in retrospect at the time of the ultrasound at baseline about the volume status is established.

The diagnostic accuracy for hypovolemia and hypervolemia cases are analyzed. The sensitivity, specificity, positive predictive value, and negative predictive value are also determined. Furthermore, the area under the curve (AUC) for hypo- and hypervolemia were computed.

A descriptive analysis of the changes over time will be carried out in the subgroup with follow-up measurements. The interpretation of the images at the time of the ultrasound serves as the foundation for the main analysis. A second assessor will verify the images retrospectively in a subset, recalculating the diameter and evaluating their quality. A descriptive analysis will be conducted on the quality of measurements. Moreover, an exploratory analysis will be carried out to ascertain the best location and cutoff points for identifying volume status.

02

Conditions studied

  • Volume Status
03

In context

Lead sponsor

Flevoziekenhuis is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients admitted to the general ward with a clinical indication for performing VCI ultrasound.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is over 18 years old.
  • Patient has a clinical indication for making a IVC ultrasound.
  • Patient is admitted until at least 24 hours after the first ultrasound.

Exclusion criteria

Exclusion Criteria:

  • Patients who are using vasopressors at the time of the ultrasound.
  • Patients who require invasive or non-invasive (optiflow, CPAP, BPAP) ventilation.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
98 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testPOCUS performed on clinical indication

    POCUS performed on clinical indication

06

What researchers measure

Primary outcomes

  1. Volume status

    Depleted, overloaded, or normal volume status at baseline, determined 48 hours after performing the ultrasound.

    Time frame: 48 hours

07

Study locations

1 site
  • Flevoziekenhuis
    Almere Stad, Netherlands
08

References and documents

Publications

  • Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol. 1990 Aug 15;66(4):493-6. doi: 10.1016/0002-9149(90)90711-9. PubMed 2386120 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Mar 2026, 24 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2025 → Mar 2026 and completion Mar 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 23, 2024
StartActual
Feb 28, 2024
Primary completionActual
Mar 1, 2026was Mar 2025
CompletionActual
Mar 1, 2026was Mar 2025
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Primary completion
Mar 2025→Mar 1, 2026 (actual)
Oct 30, 2026
Study completion
Mar 2025→Mar 1, 2026 (actual)
Oct 30, 2026
Enrollment
150 (estimated)→98 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Completed
    Primary completion Mar 2025→Mar 1, 2026 (now actual)
    Study completion Mar 2025→Mar 1, 2026 (now actual)
    Enrollment 150 (estimated)→98 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06379347
Lead sponsor
Flevoziekenhuis
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Feb 28, 2024
Primary completion
Mar 1, 2026
Completion
Mar 1, 2026
Last update
Oct 30, 2026

Study contacts

Koen de Heer, MD PhD
principal investigator · Flevoziekenhuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion